Marinus Pharmaceuticals

/files/logo_portfolio/200x200_resize_Marinus_n.png
Site:http://www.marinuspharma.com
Stage of funding:Current
Technology Area:Drug
Company's status:Public

Description

Founded in 2003, Marinus Pharmaceuticals, Inc. is a privately held specialty pharmaceutical company located in Branford, Connecticut. Marinus is dedicated to the reformulation, development, and commercialization of ganaxolone to treat serious neurological and psychiatric disorders. Ganaxolone is the most advanced neurosteroid in development for Epilepsy, Posttraumatic Stress Disorder and Fragile-X Syndrome. Marinus has completed a successful Phase 2 trial with ganaxolone in adult partial onset seizures, and a Phase 2 proof of concept PTSD study has initiated with the INTRuST Consortium. A study of ganaxolone for Fragile-X Syndrome in children is planned through the MIND Institute at University of California Davis to begin in the first half of 2012. Marinus' investors include Domain Associates, Canaan Partners, Sofinnova Ventures and Foundation Medical Partners.

Ganaxolone is a first-in-class synthetic neurosteroid being studied for the treatment of epilepsy, posttraumatic stress disorder and fragile-X syndrome.

Ganaxolone (3α-hydroxy-3β-methyl-5α-pregnan-20-one) is the 3β-methylated synthetic analog of the neurosteroid allopregnanolone, a metabolite of progesterone. In seizure disorders, extrasynaptic GABA A receptors where neurosteroids bind with high affinity have been implicated in maintaining GABA inhibitory tone counteracting neuronal hyperexcitation. Additionally, decreases in levels of allopregnanolone or neurosteroid binding site protein expression have been associated with several neuropsychiatric disorders: anxiety, posttraumatic stress disorder, depression, fragile-X syndrome, and Niemann-Pick disorder. In all of these disorders, administration of allopregnanolone in animal models or to human subjects has been shown to improve symptoms. An important distinction between allopregnanolone and ganaxolone is that while they share the same binding profile, ganaxolone does not appear to generate metabolites that have significant classical nuclear steroid hormone activity (For substance summary, please click here.) and therefore is not expected to have steroidal side effects. Ganaxolone has been administered to more than 900 healthy adult volunteers and patients in Phase 1 and Phase 2 studies. The results show ganaxolone to be well-tolerated and safe in adults, children and infants.

Return


  • 20 May 2013

    Минпромторг: РФ будет наращивать долю отечественных лекарств на рынке

    Росбалт

    Российские власти ставят перед собой задачу довести долю отечественного производства в фармацевтике до 50%, а в фармацевтической и медицинской технике — до 40%. Об этом сегодня на Первом российско-швейцарском дне инноваций выступил заместитель главы Минпромторга РФ Игорь Караваев.